Indaptus Therapeutics, Inc. (INDP) Monday announced positive data from ongoing Phase 1 Trial of Decoy20 in patients with solid tumors.
The shares are currently at $2.75, up 16.03 percent from the previous close of $2.37 on a volume of 46,341.
The company said the administration of Decoy20 in study participants at both higher and lower doses induced dozens of cytokines and chemokines, many of which have been associated with innate and/or adaptive immune responses. Additionally, the adverse events associated with Decoy20 are generally lower-grade and transient.
The data were featured in a poster presentation at the American Society of Clinical Oncology Annual Meeting on June 1 in Chicago, Illinois.
For comments and feedback: editorial@rttnews.com